Bacillus Coagulans Strain for Single-Strain Blood Glucose Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current probiotics for reducing blood glucose levels require compounding multiple strains and prebiotics, and there is a need for a single strain that can effectively manage hyperglycemia without additional components.
Innovation Solution
The use of Bacillus coagulans VHProbi C08, which is capable of utilizing various prebiotics and glucose as carbon sources, and has a metabolic pathway for reducing blood glucose, demonstrated by its efficacy in treating STZ-induced hyperglycemia in mice models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple strains and prebiotics are compounded to reduce blood glucose, then blood glucose reduction efficacy is improved, but product complexity and manufacturing cost increase
Solution Approach 1:
The patent extracts and isolates the blood glucose reduction function into a single probiotic strain (Bacillus coagulans) that possesses this capability inherently, eliminating the need to compound multiple strains and prebiotics. This single-strain approach maintains therapeutic efficacy while simplifying the product formulation and manufacturing process
Solution Approach 2:
The Bacillus coagulans strain demonstrated in the patent exhibits multiple functions including blood glucose reduction, cholesterol lowering, and immune regulation, allowing a single strain to replace what previously required multiple components working together
2Reliability
If multiple strains and prebiotics are used for blood glucose reduction, then therapeutic effect is improved, but manufacturing cost and process complexity increase
Solution Approach 1:
The invention extracts the blood glucose reduction function into a single probiotic strain (Bacillus coagulans) that possesses this capability inherently, eliminating the need to compound multiple strains and prebiotics. This single-strain approach maintains therapeutic efficacy while simplifying the product formulation and manufacturing process
3Ease of manufacture
If a single strain is used to reduce blood glucose, then product simplicity and manufacturing ease are improved, but blood glucose reduction efficacy may be insufficient
Solution Approach 1:
The patent utilizes parameter changes in the form of metabolic byproducts (short-chain fatty acids, organic acids, gases, and heat) produced by the Bacillus coagulans strain during fermentation of prebiotic substrates. These metabolic parameters directly contribute to blood glucose reduction while maintaining a simple single-strain formulation that is easy to manufacture
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Bacillus coagulans VHProbi C08 effectively reduces blood glucose levels in hyperglycemic models, showing significant glucose level reductions of up to 46.46% in pre-treatment and 27.6% in post-treatment groups, with no toxic effects, making it suitable for functional foods.
Implementation Method 1
The Bacillus coagulans VHProbi C08 provided by the present invention has the efficacy of reducing blood glucose. The hyperglycemia model mice induced by STZ were treated with the Bacillus coagulans VHProbi C08 provided by the present invention, and the symptoms of hyperglycemia thereof were significantly relieved compared with the placebo group
Data Source
AI summary
Provided are a Bacillus coagulans strain VHProbi C08 having a blood glucose reduction efficacy and an application thereof in preparation of a hypoglycemic product. The accession number of the strain is CCTCCM 2019738. Further provided is a hypoglycemic product comprising the Bacillus coagulans VHProbi C08 and/or the fermentation product of Bacillus coagulans VHProbi C08. A carbon source used in the culture medium of the strain is any one or more of fructooligosaccharide, galactooligosaccharides, and inulin.